CSIMarket
 
Prokidney Corp   (NASDAQ: PROK)
Other Ticker:  
 
 
Price: $1.5600 $-0.10 -6.024%
Day's High: $1.68 Week Perf: 0.65 %
Day's Low: $ 1.55 30 Day Perf: -14.75 %
Volume (M): 288 52 Wk High: $ 4.44
Volume (M$): $ 450 52 Wk Avg: $2.10
Open: $1.64 52 Wk Low: $1.18



 Market Capitalization (Millions $) 197
 Shares Outstanding (Millions) 126
 Employees 110
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -137
 Cash Flow (TTM) (Millions $) -83
 Capital Exp. (TTM) (Millions $) 6

Prokidney Corp
Prokidney Corp is a medical company that specializes in the development and manufacturing of innovative products for kidney care and treatment. They cater to patients with kidney diseases and disorders, providing them with advanced solutions to improve their quality of life. Prokidney Corp is known for its cutting-edge technology and research in the field of nephrology, constantly striving to find new and effective treatments for kidney-related ailments. They work closely with healthcare professionals to ensure the best outcomes for their patients, and their products are widely used in hospitals and healthcare facilities worldwide.


   Company Address: 2000 Frontis Plaza Blvd. Winston-Salem 27103 NC
   Company Phone Number: 999-7019   Stock Exchange / Ticker: NASDAQ PROK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN        1.62% 
BCRX        14.44% 
BIIB   -0.7%    
EXEL        1.82% 
GILD   -2.38%    
RGNX        4.99% 
• View Complete Report
   



Management Announcement

ProKidney Corp Raises $140 Million in Public and Direct Offering, Fueling Breakthroughs in Chronic Kidney Disease Therapeutics

Published Mon, Jun 17 2024 11:00 AM UTC

ProKidney Corp Announces Successful Closing of $140 Million Public Offering and Registered Direct Offering
ProKidney Corp, a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, has recently completed a significant financial milestone. The company has successfully closed a public offering and concurrent registered direct offering,...

Shares

ProKidney Corp. Raises $125 Million in Public Offering to Combat Chronic Kidney Disease

Published Mon, Jun 10 2024 8:15 PM UTC

ProKidney Corp. Announces $125 Million Public Offering to Advance Treatment for Chronic Kidney Disease
ProKidney Corp., a leading cellular therapeutics company specializing in chronic kidney disease, has just announced a significant financial move to further advance its groundbreaking treatments. The company, listed on Nasdaq under the ticker symbol PROK, has kicked off ...

Clinical Study

ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

Published Mon, Jun 10 2024 10:30 AM UTC

Renal Autologous Cell Therapy Shows Promise: Interim Results from ProKidney s REGEN-007 Phase 2 Trial Authors: Author Names, CSIMarket.com In a recent announcement, ProKidney Corp. (Nasdaq: PROK), a prominent late clinical-stage cellular therapeutics company specializing in chronic kidney disease (CKD), has reported encouraging interim results from its Phase 2 REGEN-007 tr...

Clinical Study

ProKidney Corp. Ushers in a Promising Era for CKD Treatment with Strong First Quarter Results

Published Fri, May 10 2024 11:01 AM UTC

ProKidney Corp. Reports Positive Business Updates and First Quarter Financial ResultsProKidney Corp., a renowned late-stage cellular therapeutics company specializing in chronic kidney disease (CKD), has recently released its business updates and financial results for the first quarter ending March 31, 2024. The positive outcomes highlight the company s progress in its missi...

Management Changes

ProKidney's Strategic Leadership Appointments to Drive Clinical and Technical Excellence Amid Financial Challenges

Published Mon, Mar 25 2024 10:05 AM UTC

ProKidney Strengthens Clinical and Technical Operations with Key Leadership Appointments
ProKidney, a prominent player in the healthcare sector, has recently announced significant leadership appointments aimed at bolstering its clinical and technical operations. Dr. Ulrich Ernst has joined the company as the Executive Vice President of Technical Operations, bringing with...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com